Alexion Investors Advance Securities Suit Over Soliris Tactics

Alexion Pharmaceuticals Inc. must face a securities lawsuit claiming it misled investors about the unethical sales practices it used to push patients into the drug accounting for 99% of its revenue, a ruling in Connecticut federal court shows.

Alexion investors are moving forward with claims that the company made misleading statements about the success of Soliris, an “orphan drug"—drugs treating a disease affecting fewer than 200,000 people in the U.S.—reducing the symptoms associated with two rare diseases and treating about 11,000 people worldwide. Judge Alvin W. Thompson of the U.S. District Court for the District of Connecticut on Thursday greenlighted ...